RxDoctor Payments Data

David Shusterman, MD

Urology · New York, NYNPI 1215138342

Payments from drug & device makers

$10,318in general payments, 2019–2025

Across 193 payments — averaging $53.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acerus Pharmaceuticals Corporation$5K
  • Astellas Pharma US Inc$697
  • Boston Scientific$480
  • AbbVie$322
  • Terumo Medical Corporation$313
  • Teleflex LLC$297
  • plus $4K from 42 others

What the payments were for

  • Consulting fees$3,85037%
  • Speaking & faculty fees$1311%
  • Travel & lodging$3373%
  • Food & beverage$5,90057%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,318 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$336,612
Medicare patients
471
Services billed
7,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate19$102,856
MyrbetriqMirabegron19$8,006
GemtesaVibegron12$7,221
Alfuzosin Hcl ErAlfuzosin Hcl176$1,686
Darifenacin ErDarifenacin Hydrobromide11$844
Tamsulosin Hcl28$215
Cefdinir15$92
Ciprofloxacin Hcl32$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$322$102,85619 claims
Astellas Pharma US IncMyrbetriq$697$8,00619 claims
Sumitomo Pharma America, Inc.Gemtesa$184$7,22112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →